Bradley L Smith
Overview
Explore the profile of Bradley L Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ochieng E, Robinson V, Anderson E, Niles-Carnes L, Smith B, Armstrong W, et al.
Open Forum Infect Dis
. 2025 Mar;
12(3):ofaf096.
PMID: 40046888
We leveraged a long-acting antiretroviral therapy program infrastructure in the US South to vaccinate 32 of 39 (82%) eligible persons with HIV against hepatitis B virus. Novel interprofessional programmatic synergy...
2.
Haser G, Balter L, Gurley S, Thomas M, Murphy T, Sumitani J, et al.
AIDS Res Hum Retroviruses
. 2024 Jul;
40(12):690-700.
PMID: 38959116
The use of long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) as maintenance therapy for persons with HIV (PWH), which may improve treatment access and outcomes, though real-world data on uptake are limited, was...
3.
Rivera C, Zeuli J, Smith B, Johnson T, Bhatia R, Otto A, et al.
Drugs
. 2023 Dec;
83(18):1677-1698.
PMID: 38079092
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) provides a critical intervention toward ending the HIV epidemic and protecting people with reasons to utilize PrEP. PrEP options continue to expand as...
4.
Zeuli J, Rivera C, Smith B, Otto A, Temesgen Z
Drugs Today (Barc)
. 2023 Jan;
58(12):555-576.
PMID: 36651065
Cabotegravir, a novel HIV integrase inhibitor, shares structural similarity with dolutegravir and bictegravir. Its oral half-life is 32 hours, but cabotegravir nanosuspension for intramuscular injection yields half-lives ranging from 25...
5.
Collins L, Corbin-Johnson D, Asrat M, Morton Z, Dance K, Condra A, et al.
Open Forum Infect Dis
. 2022 Sep;
9(9):ofac455.
PMID: 36147599
Background: Long-acting injectable (LAI) antiretroviral therapy (ART) has the potential to improve medication adherence, reduce human immunodeficiency virus (HIV) stigma, and promote equity in care outcomes among people with HIV...
6.
Aldredge A, Roth G, Vaidya A, Duarte A, Kundu S, Zheng Z, et al.
AIDS
. 2021 Jan;
35(3):524-526.
PMID: 33507011
No abstract available.
7.
Smith B, Griffin M, Heyliger A, Ritchie B
Am J Health Syst Pharm
. 2020 Jan;
77(Supplement_1):S8-S12.
PMID: 31961922
Purpose: Hospital emergency medication kits (HEMKs) are used to provide certain critical medications in emergent situations, despite many technological advancements for patient safety and medication distribution. We sought to evaluate...
8.
Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, et al.
Clin Cancer Res
. 2009 Apr;
15(9):3023-8.
PMID: 19366827
Purpose: Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non-small-cell lung cancer (NSCLC) patients and are associated...
9.
Wetzel R, Goss V, Norris B, Popova L, Melnick M, Smith B
J Immunol Methods
. 2005 Sep;
305(1):59-66.
PMID: 16169003
Our understanding of the mechanisms by which BCR-ABL drives CML is based, in part, on the use of model cell lines such as the K562 cell line. However, the BCR-ABL...
10.
Thomas G, Horvath S, Smith B, Crosby K, Lebel L, Schrage M, et al.
Clin Cancer Res
. 2004 Dec;
10(24):8351-6.
PMID: 15623612
Purpose: As kinase inhibitors transition from the laboratory to patients, it is imperative to develop biomarkers that can be used in the clinic. The primary objectives are to identify patients...